Amylin/GLP-1Investigational · Phase 3

Amycretin

Last updated

GLP-1 and amylin receptor agonist. Once weekly (injectable); once daily (oral).

Amycretin (investigational)·Novo Nordisk

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells amycretin; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • 60 mg weekly (Phase 1b/2a)Phase 1b/2a (subcutaneous) · 36 wks
    −24.3% (thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))about 49 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

Investigational: not FDA-approved for this or any use. It is still being studied in trials.

Information from FDA labels and published trials, not medical advice.

What to know about Amycretin

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−24.3% (thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))

Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once weekly (injectable); once daily (oral)

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Indications

Investigational uses

Amycretin (investigational)

Obesity; type 2 diabetes (investigational)

An investigational single molecule that agonizes both the GLP-1 and amylin receptors, in development as both a once-weekly injection and a once-daily oral tablet.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Amycretin is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Evidence

Clinical trials

1 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov/study/NCT06049329)
    NCT06049329PHASE1Completed36 enrolled

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
Related

Related GLP-1s to compare

From PubMed

Latest Amycretin trials and reviews

  • Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (pubmed.ncbi.nlm.nih.gov/40550231)

    Randomized trial · Lancet · Jun 20, 2025 · Dahl K et al. · cited by 70

  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/40550229)

    Randomized trial · Lancet · Jun 20, 2025 · Gasiorek A et al. · cited by 37

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Amycretin

How much weight can you lose on Amycretin?
In its pivotal trial (Phase 1b/2a (subcutaneous)), Amycretin at 60 mg weekly (Phase 1b/2a) showed a mean body-weight change of -24.3% at 36 wks. This is a trial average; individual results vary. Source (thelancet.com)
Is Amycretin available yet?
No. Amycretin is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
When will Amycretin be FDA approved?
FDA has not approved Amycretin, and no public record gives an approval date. It is at this stage: Phase 3. Source
Can you buy Amycretin?
Not legally: FDA has not approved it, so no pharmacy can fill it. FDA has warned companies selling unapproved GLP-1 drugs labeled for research, and says: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." Source (fda.gov)
How much does Amycretin cost?
It has no legal price, because it is not approved and nobody can legally sell it. Prices online are for unapproved products of unknown quality. What approved GLP-1s cost is on our price pages. Source
Does insurance cover Amycretin?
No. It is not FDA approved, so it is on no plan's list, and an HSA or FSA has nothing legal to pay for. Coverage could only come after an approval. Source
Is there a generic Amycretin?
No. It has no approved brand to copy. Anything sold as a generic of it is an unapproved product. Source
What is the Amycretin dose?
There is no approved dose, because it has no FDA label. The result we cite was at 60 mg weekly (Phase 1b/2a). We do not publish dosing, units or mixing charts for an unapproved medicine: those charts online describe products FDA warns against.
How does Amycretin work?
An investigational single molecule that agonizes both the GLP-1 and amylin receptors, in development as both a once-weekly injection and a once-daily oral tablet.
Is Amycretin a GLP-1?
GLP-1 and amylin receptor agonist. Source
Who makes Amycretin?
Novo Nordisk.
Can you join a Amycretin trial?
A clinical trial is one legal way to receive a medicine FDA has not approved, but none of its registered trials is recruiting on ClinicalTrials.gov now. Source (clinicaltrials.gov)